Altheos Secures $20,000,000 Series A Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    400 Oyster Point Boulevard South San Francisco, CA 94080
  • Company Description
    Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.
  • M&A Terms
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Novo A/S
  • Venture Investor
    Canaan Partners
  • Venture Investor
    Life Science Angels
  • Venture Investor

Trending on Xconomy